Our mission is to build an IO community to improve patient care


The Immuno-Oncology Clinical Network was established in 2022 by Dr Anna Olsson-Brown and a team of trustees with a passion for improving the care of cancer patients receiving immunotherapy treatment. Dr Olsson-Brown recognised the need to build a multi-disciplinary and 

multi-specialty community to support healthcare professionals manage the complexities of Immuno-oncology treatments including the auto-immune side effects. The Immuno-Oncology Clinical Network applied for charitable status in Spring 2023. 


To support health care professionals delivering immuno-oncology therapies to improve patient care through clinical support, education, service development and governance

 To promote and support research or any activities that will progress knowledge and understanding of immuno-oncology treatments and the associated side effects.


Dr Anna Olsson- Brown

IOCN Founder

CEO & Trustee

Dr Ricky Frazer 

IOCN Deputy CEO & Trustee

Trudy Guinan

IOCN Trustee

Dr Brent O'Carrigan 

IOCN Trustee

Dr Clare Barlow

IOCN Trustee

Dr Kate Young 

IOCN Trustee 

Dr Alexandra Johnson 

IOCN Director of Operations & Trustee

Anna Olsson-Brown is a Consultant in Medical Oncology. She specialises in the systemic treatment of skin cancers; sarcoma; immunotherapeutic toxicities, and early phase/translational clinical trials. She is the Clinical Director for the Acute Division at the Clatterbridge Cancer Centre, Liverpool and an Honorary Senior Lecturer at the University of Liverpool. She has a background in clinical pharmacology and specialises in the management of immunotherapeutic toxicities, melanoma, sarcoma and early phase/ translational clinical trials. She has an interest in acute oncology and supportive care for cancer patients particularly with regards to toxicity of cancer therapies. She was an MRC research fellow completing her PhD investigating the mechanisms of immunotherapy toxicity and has subsequently published extensively in the area. She established and leads a pan-tumour, pan-regional immunotherapy toxicity service supporting inpatients and outpatients with immunotherapy toxicities.  She is the current immunotherapy toxicity work stream lead for the NIHR Oncology Translational Research Committee (O-TRC) and a board member of UKASC. She is a founding member and current CEO of the National Immunotherapy Clinical Network (IOCN) and sits on the UK Chemotherapy Board within this role. Within Clatterbridge she is the Chair of the Immunotherapy Committee and Deputy Chair of Supportive Care SRG. She is a current Clinical Advisor to Health Education England and the British Medical Journal, Oncology representative of the Symposium Committee at the Royal College of Physicians of Edinburgh, representative on the Association of Cancer Physicians and RCPE new consultant committees and senior advisor to the National Oncology Collaboration for Trainee Research (NOTCH).

Ricky Frazer is a medical oncology consultant working at Velindre Cancer Centre (VCC) in Cardiff. He specialises in renal cancer, skin cancer and acute oncology and is clinical lead for the acute oncology assessment unit at VCC and the immunotherapy toxicity management service. He is one of the founding members of the UK Renal Oncology Collaborative (UK ROC). He has recently completed and was awarded a distinction in the postgraduate certificate in acute medicine at the University of South Wales. He was a Welsh Clinical Leadership Training Fellow with the Wales Deanery and is a Founding Associate Fellow of the Faculty of Medical Leadership and Management. He has a strong educational interest and is currently a Royal College of Physicians (RCP) College Tutor and Faculty Lead. He is also an Honorary Lecturer at Cardiff University. He has completed a Master’s in medical education and was awarded the National Munro Medal by the RCP for excellence and leadership in education. He is Vice President of the National Immuno-Oncology Clinical Network (I-OCN) and co-chairs the monthly National Immuno-Oncology Education Forum. He has been heavily involved in the inception and development of the national Practical Management of your Immuno-Oncology Patient (PMI-OP) educational series exploring immunotherapy identification and management with specialist colleagues. He is co-founder of a Podcast called ‘The Immunobuddies’ launched in 2023 which covers the use and management of immunotherapy in treating cancer. The podcast is freely available on a number of online platforms including Spotify!

Trudy-Jane Guinan has worked in the field of Oncology for over 19 years, working at The Clatterbridge Cancer Centre as an Advanced Nurse Practitioner and Lead Immunotherapy Nurse. During the past 5 years she has worked with Dr Anna Olsson-Brown setting up the UK’s first Immuno-oncology service at the Cancer Centre, the service has received national recognition (Radio Interviews, ITV’s This morning, BBC Northwest piece) and won an award for innovation in the 2020 BJN Awards.  She regularly provides ongoing specialist support and advice to those involved in the delivery of IO across the country, speaks at National conferences and has run and presented at Immunotherapy workshops at The Clatterbridge for national delegates as well as speaking at national conferences. Trudy has completed her Masters in Advanced Clinical Practice focusing her dissertation on the impact of a centralised IO service at the cancer centre, which has been accepted by the BJN for publication. Following on from all her hard work and dedication she was then appointed as Nurse Consultant specialising in Immuno-oncology.

Dr O’Carrigan is a consultant medical oncologist specialising in melanoma and kidney cancer at Addenbrooke’s Hospital, Cambridge. He trained in Sydney and London, completing a fellowship in early phase oncology trials at the Royal Marsden Hospital and PhD in translational cancer research in immuno-oncology at the University of Cambridge. He is PI for a broad portfolio of academic and commercial clinical trials including cellular therapy trials. He is regional chair of the Immunotherapy Toxicity Working group and Clinical Cancer Lead for the NHS Eastern Genomics Laboratory Hub (GLH).

Dr Barlow is a consultant Medical Oncologist specialising in the treatment of melanoma and ovarian cancer. She was appointed to her role at Musgrove Park Hospital Taunton in 2009. Dr Barlow is lead for the immunotherapy service at Musgrove Park and is chair of the South West Immunotherapy Group, a regional immunotherapy forum. In other roles she is the South West Peninsula Clinical Research Network sub-specialty research lead for gynaecological cancer and is a member of the South West Clinical Senate Council.

Dr Barlow is Principal Investigator for a varied portfolio of Phase II and Phase III clinical trials at Musgrove Park Hospital. Dr Barlow is also the current UK SACT board IOCN Representative. 

Dr Barlow trained at St George’s Hospital, London and underwent specialist training in Medical Oncology at St Bartholomew’s Hospital, London. She was awarded a PhD in Molecular Pharmacology in 2009, following laboratory-based research at the Institute of Cancer Research London, sponsored by a CRUK grant. 

Dr Kate Young is a Consultant Medical Oncologist at the Royal Marsden Hospital, specialising in Renal and Skin Cancers and is the Unit Lead for the Acute Oncology Service.  Kate took a first in Natural Sciences from Cambridge University and completed her clinical training at Imperial, qualifying in 2004. She underwent general medical training in London and specialist training at the Royal Marsden, where she was appointed a consultant in 2020. Kate completed an Md(res.) at the Institute of Cancer Research and her research interests include survivorship and toxicities associated with immunotherapies. 

Dr Alexandra Johnson is a Medical Oncology Registrar at the Clatterbridge Cancer Centre Liverpool and current Senior Clinical Fellow in Immunotherapy. She underwent general medical training in the South West before starting specialist training at the Clatterbridge Cancer Centre in Liverpool. She has an interest in acute oncology, immunotherapy toxicities, Renal cancer and cancer survivorship.